文献速递乳腺癌

综合遗传风险评估用于女性基于风险的乳腺癌筛查

Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women.
PubMed 文献 · J Clin Oncol · 2024-02-29

该研究利用芬兰FinnGen队列(N=117,252)与全国乳腺癌筛查登记数据(1992-2019年,50-69岁女性每两年一次组织性筛查),评估乳腺癌多基因风险评分(PRS)的筛查表现,并与乳腺癌家族史(FH)及中高风险易感基因(CHEK2、PALB2)致病性变异(PVs)进行比较。结果显示,高PRS(>90百分位)与FH、PVs在筛查年龄段女性中的效应量相当,对筛查起始年龄调整有相似意义;高PRS女性筛查阳性后确诊乳腺癌的阳性预测值(PPV)为39.5%(95%CI 37.6-41.5),联合风险因素后PPV可升至45%-50%;高PRS与间隔期乳腺癌风险升高相关(50岁时HR 2.78,95%CI 2.00-3.86;60岁时HR 2.48,95%CI 1.67-3.70),低PRS(<10百分位)女性间隔期和筛查检出乳腺癌风险均较低。结论认为PRS可有效用于风险分层,单独或联合FH和PVs使用,但需进一步研究评估其在前瞻性风险分层筛查项目中的影响及成本效益。

要点

  • 高PRS(>90百分位)与FH、PVs在筛查年龄段女性中效应量相当,对筛查起始年龄调整意义相似。
  • 高PRS女性筛查阳性后确诊乳腺癌的PPV为39.5%(95%CI 37.6-41.5),联合风险因素后PPV升至45%-50%。
  • 高PRS与间隔期乳腺癌风险升高相关(50岁HR 2.78,95%CI 2.00-3.86;60岁HR 2.48,95%CI 1.67-3.70),低PRS(<10百分位)女性间隔期和筛查检出乳腺癌风险均低。

核心结论

  • 利用真实世界筛查数据,本研究表明乳腺癌PRS可有效进行风险分层,单独或联合FH和PVs使用。
  • 需进一步研究评估其在前瞻性风险分层筛查项目中的影响,包括成本效益。

研究设计与样本

  • 纵向真实世界数据研究,使用FinnGen队列(N=117,252),链接至乳腺癌群体筛查登记(1992-2019年;全国组织性每两年一次筛查,年龄50-69岁)。
  • 评估乳腺癌PRS的筛查表现,并与乳腺癌FH及中高风险易感基因(CHEK2、PALB2)PVs进行比较。

主要发现

  • FH、PVs和高PRS(>90百分位)在筛查年龄段女性中效应量相当,对筛查起始年龄调整有相似意义。
  • 高PRS女性筛查阳性后确诊乳腺癌的PPV为39.5%(95%CI 37.6-41.5)。
  • 风险因素组合使PPV升高至45%-50%。
  • 高PRS与间隔期乳腺癌风险升高相关:50岁时HR 2.78(95%CI 2.00-3.86),60岁时HR 2.48(95%CI 1.67-3.70)。
  • 低PRS(<10百分位)女性间隔期和筛查检出乳腺癌风险均较低。

局限性

  • 需进一步研究评估PRS在前瞻性风险分层筛查项目中的影响,包括成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Family history (FH) and pathogenic variants (PVs) are used for guiding risk surveillance in selected high-risk women but little is known about their impact for breast cancer screening on population level. In addition, polygenic risk scores (PRSs) have been shown to efficiently stratify breast cancer risk through combining information about common genetic factors into one measure. METHODS: In longitudinal real-life data, we evaluate PRS, FH, and PVs for stratified screening. Using FinnGen (N = 117,252), linked to the Mass Screening Registry for breast cancer (1992-2019; nationwide organized biennial screening for age 50-69 years), we assessed the screening performance of a breast cancer PRS and compared its performance with FH of breast cancer and PVs in moderate- (CHEK2)- to high-risk (PALB2) susceptibility genes. RESULTS: Effect sizes for FH, PVs, and high PRS (>90th percentile) were comparable in screening-aged women, with similar implications for shifting age at screening onset. A high PRS identified women more likely to be diagnosed with breast cancer after a positive screening finding (positive predictive value [PPV], 39.5% [95% CI, 37.6 to 41.5]). Combinations of risk factors increased the PPVs up to 45% to 50%. A high PRS conferred an elevated risk of interval breast cancer (hazard ratio [HR], 2.78 [95% CI, 2.00 to 3.86] at age 50 years; HR, 2.48 [95% CI, 1.67 to 3.70] at age 60 years), and women with a low PRS (<10th percentile) had a low risk for both interval- and screen-detected breast cancers. CONCLUSION: Using real-life screening data, this study demonstrates the effectiveness of a breast cancer PRS for risk stratification, alone and combined with FH and PVs. Further research is required to evaluate their impact in a prospective risk-stratified screening program, including cost-effectiveness.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Mars N, Kerminen S, Tamlander M, et al. Comprehensive Inherited Risk Estimation for Risk-Based Breast Cancer Screening in Women. J Clin Oncol. 2024. PMID: 38422475. doi:10.1200/JCO.23.00295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。